Corporate Profile for VaxGen Inc., dated Feb. 12, 1999.--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0-
Published Date: Feb. 12, 1999
Company Name: VaxGen Inc.
Address: 1000 Marina Boulevard
Brisbane, CA 94005
Main Telephone
Number: 650/624-1000
Internet Home
Page Address
(URL) www.vaxgen.com
Chairman: Robert Nowinski
President: Donald Francis
Chief Financial
Officer: Robert Pacquer
Public Relations
Contact: Nicole Lynch
Business number: 650/624-1065
Industry: Biotechnology
-0- Company description: VaxGen Inc. was formed in 1995 to develop and market an HIV vaccine HIV vaccine AIDS As of mid-2005, there is no viable anti-HIV vaccine. See AIDS. . The co-founders of the firm are Dr. Donald P. Francis, its President, and Dr. Robert Nowinski, its Chairman -- both retrovirologists with extensive backgrounds in HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. research. VaxGen continues essential research begun at Genentech Inc., in 1984, where Dr. Phillip Berman, now VaxGen's Vice President of Research, directed Genentech's HIV vaccine research team. VaxGen's ongoing research has led to the development of AIDSVAX, a vaccine designed to provide protection against the major strains of HIV in the Americas, Western Europe Western Europe The countries of western Europe, especially those that are allied with the United States and Canada in the North Atlantic Treaty Organization (established 1949 and usually known as NATO). and Southeast Asia. Two formulations of the new bivalent bivalent /bi·va·lent/ (bi-va´lent) 1. divalent. 2. the structure formed by a pair of homologous chromosomes by synapsis along their length during the zygotene and pachytene stages of the first meiotic prophase. AIDSVAX have been studied in Phase I/II confirmatory trials at multiple sites in the United States and Thailand. On June 3, 1998, the company announced that it received FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. go-ahead for the first-ever large scale clinical trial of a preventative HIV vaccine, and began inoculation inoculation, in medicine, introduction of a preparation into the tissues or fluids of the body for the purpose of preventing or curing certain diseases. The preparation is usually a weakened culture of the agent causing the disease, as in vaccination against of the first volunteers on June 23, 1998. Phase III trials of AIDSVAX in Thailand will begin in February 1999, under the direction of Dr. Nzeera Virani-Ketter, VaxGen's Senior Director of Medical Affairs. VaxGen is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. , based in Brisbane, Calif., with 45 employees. Serving on its board of directors are Drs. Francis, Nowinski and Berman; Randall Caudill, President of Dunsford Hill Capital Partners, a San Francisco-based financial consulting firm; Stephen C. Francis, Co-founder and Vice Chairman of Fischer, Francis, Trees and Watts, a worldwide manager of fixed-income portfolios; Daniel T. Reiner, a founder and former Chief Executive of several high-technology and manufacturing companies; and William D. Young, Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. of Genentech. Additional information on VaxGen and AIDSVAX is available on the company's website at: www.vaxgen.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion